ATE273323T1 - INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN - Google Patents

INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN

Info

Publication number
ATE273323T1
ATE273323T1 AT00979875T AT00979875T ATE273323T1 AT E273323 T1 ATE273323 T1 AT E273323T1 AT 00979875 T AT00979875 T AT 00979875T AT 00979875 T AT00979875 T AT 00979875T AT E273323 T1 ATE273323 T1 AT E273323T1
Authority
AT
Austria
Prior art keywords
stable
ßframeworkß
intrabody
reducing environment
defined structure
Prior art date
Application number
AT00979875T
Other languages
English (en)
Inventor
Adrian Auf Der Maur
Alcide Barberis
Dominik Escher
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Ag filed Critical Esbatech Ag
Application granted granted Critical
Publication of ATE273323T1 publication Critical patent/ATE273323T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Stored Programmes (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Catalysts (AREA)
AT00979875T 1999-12-28 2000-12-18 INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN ATE273323T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB9902054 1999-12-28
IBPCT/IB00/00218 2000-03-01
PCT/IB2000/001892 WO2001048017A1 (en) 1999-12-28 2000-12-18 Intrabodies with defined framework that is stable in a reducing environment and applications thereof

Publications (1)

Publication Number Publication Date
ATE273323T1 true ATE273323T1 (de) 2004-08-15

Family

ID=26318608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979875T ATE273323T1 (de) 1999-12-28 2000-12-18 INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN

Country Status (10)

Country Link
US (3) US7258986B2 (de)
EP (3) EP1242457B1 (de)
JP (4) JP4698109B2 (de)
AT (1) ATE273323T1 (de)
AU (1) AU768827B2 (de)
CA (1) CA2396534C (de)
DE (1) DE60012980T2 (de)
DK (1) DK1242457T3 (de)
ES (1) ES2225269T3 (de)
WO (1) WO2001048017A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
IT1317922B1 (it) * 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
AU2012211497C1 (en) * 2002-05-22 2021-07-29 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2013203288B2 (en) * 2002-05-22 2015-04-23 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2015202410B2 (en) * 2002-05-22 2017-09-14 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CN103739706B (zh) 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
EP1621616A4 (de) * 2003-04-30 2007-07-04 Japan Science & Tech Agency Menschlicher anti-mensch-interleukin-18-antikörper, fragment davon und verfahren zu deren verwendung
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
AU2005207003C1 (en) * 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
KR100635370B1 (ko) 2005-03-04 2006-10-17 주식회사 녹십자홀딩스 ＳｃＦｖ 형태의 항체 라이브러리를 제작하기 위한 항체 ＳｃＦｖ 발현벡터
EP2338999A3 (de) * 2005-03-25 2012-05-23 National Research Council Of Canada Verfahren zur Isolation von löslichen Polypeptiden
FR2883886B1 (fr) * 2005-04-05 2010-12-03 Biomethodes Methode d'obtention de variants solubles ou mieux exprimes d'une proteine d'interet
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
JP4938263B2 (ja) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
WO2007024877A2 (en) * 2005-08-22 2007-03-01 Cornell Research Foundation, Inc. Compositions and methods for analyzing protein interactions
DK2013236T3 (en) 2006-04-28 2015-09-21 Delenex Therapeutics Ag ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK
ES2820837T3 (es) * 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US8722584B2 (en) * 2007-01-12 2014-05-13 Cornell University Genetic selection for protein folding and solubility in the bacterial periplasm
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
WO2008110914A2 (en) 2007-03-15 2008-09-18 Inserm Methods for producing active scfv antibodies and libraries therefor
KR101530723B1 (ko) * 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
SI2158315T1 (sl) * 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
EP3216803B1 (de) 2008-06-25 2020-03-11 Novartis Ag Stabile und lösliche, vegf-inhibierende antikörper
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
JP6100463B2 (ja) 2008-06-25 2017-03-22 エスバテック − ア ノバルティス カンパニー エルエルシー ＴＮＦαを阻害する安定かつ可溶性の抗体
CA2728004C (en) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
CN104884470A (zh) * 2013-02-15 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的接受体框架
CN104884471A (zh) 2013-02-20 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的受体框架
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
US20170219596A1 (en) * 2014-07-14 2017-08-03 The Regents Of The University Of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
KR102537102B1 (ko) 2015-05-29 2023-05-25 엠피베나 테라퓨틱스, 인크. 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
JP7149935B2 (ja) 2016-10-19 2022-10-07 ザ スクリプス リサーチ インスティテュート ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
EP4085919A3 (de) 2017-07-21 2023-02-08 Novartis AG Zusammensetzungen und verfahren zur behandlung von krebs
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
US20200102373A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
WO2023229535A1 (en) 2022-05-27 2023-11-30 Engine Biosciences Pte. Ltd. Bet polypeptide therapeutic agents for generating synthetic lethality in tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
FR2627508B1 (fr) 1988-02-22 1990-10-05 Eurolysine Procede pour l'integration d'un gene choisi sur le chromosome d'une bacterie et bacterie obtenue par ledit procede
FR2648713B1 (fr) 1989-06-26 1994-06-10 Commissariat Energie Atomique Proteines hybrides entre une enzyme extracytoplasmique et une autre proteine, leur procede de preparation, ainsi que leur application comme agent de diagnostic
EP0590067A1 (de) 1991-06-14 1994-04-06 Xoma Corporation Mikrobiell hergestellte antikörper-fragmente und deren konjugate
JPH05105700A (ja) 1991-07-15 1993-04-27 Tosoh Corp 酵母に対する血清又は抗体、それらの調製方法及びそれらの使用方法
JPH0597704A (ja) 1991-10-07 1993-04-20 Hisashi Ishihara 新抗体ワクチン製造技法
JPH0630778A (ja) 1992-07-17 1994-02-08 Tosoh Corp ピキア酵母により抗体を製造するためのベクタ−、該ベクタ−で形質転換されたピキア酵母及び形質転換ピキア酵母を培養することを特徴とする抗体の製造方法
EP0698097B1 (de) 1993-04-29 2001-08-16 Unilever N.V. Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
JPH0920798A (ja) 1995-07-11 1997-01-21 Asahi Chem Ind Co Ltd ヒト抗ＨＢｓ抗体
DE69722176T2 (de) * 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20030017149A1 (en) * 1996-10-10 2003-01-23 Hoeffler James P. Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
JP4041913B2 (ja) 1997-02-13 2008-02-06 独立行政法人農業・食品産業技術総合研究機構 抗腫瘍タンパク質およびその遺伝子
JPH11174A (ja) 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins

Also Published As

Publication number Publication date
JP5783703B2 (ja) 2015-09-24
AU768827B2 (en) 2004-01-08
JP4698109B2 (ja) 2011-06-08
US20010024831A1 (en) 2001-09-27
EP1242457B1 (de) 2004-08-11
EP1479694A3 (de) 2010-05-05
JP2011062205A (ja) 2011-03-31
ES2225269T3 (es) 2005-03-16
JP2016020388A (ja) 2016-02-04
US7258985B2 (en) 2007-08-21
WO2001048017A1 (en) 2001-07-05
DK1242457T3 (da) 2004-12-20
EP2392596A2 (de) 2011-12-07
JP2004504007A (ja) 2004-02-12
JP2013224294A (ja) 2013-10-31
EP1479694B1 (de) 2016-10-26
CA2396534A1 (en) 2001-07-05
DE60012980T2 (de) 2005-08-18
US20080233110A1 (en) 2008-09-25
EP1479694A2 (de) 2004-11-24
DE60012980D1 (de) 2004-09-16
AU1725201A (en) 2001-07-09
CA2396534C (en) 2012-10-02
EP1242457A1 (de) 2002-09-25
US20030096306A1 (en) 2003-05-22
EP2392596A3 (de) 2013-11-27
US7258986B2 (en) 2007-08-21

Similar Documents

Publication Publication Date Title
ATE273323T1 (de) INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
IT1318730B1 (it) Struttura artificiale d'arrampicata.
SE9900100D0 (sv) New compounds
FI933942A0 (fi) Cykliska ureaderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
FI933824A0 (fi) Matkustajien kuljetuslaite ja sitä varten tarkoitettu vaihtoaskelma sekä kuljetuslaitteen askelmaan liittyvät muunto- ja valmistusmenetelmät
DE60010098D1 (de) 28-epirapaloge
DE60044515D1 (de) Azithromycinmonohydrat
DE60234409D1 (de) Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
NO913362L (no) Gassturbin for kraftproduksjon.
DE69925133D1 (de) Pyrrolobenzodiazepine
FI924687A0 (fi) Heterobiarylderivat, dessa foereningar innehaollande laekemedel och foerfarande foer deras framstaellning
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
FI932649A (fi) Bifenylderivat, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning
AU2001266575A1 (en) Chemical compounds
NO931534L (no) Sulfonylbenzylsubstituerte benzo- og pyridopyridoner
DE69941786D1 (de) Chemolumineszente 1,2-dioxetane
DE59201298D1 (de) Naturzug-Kühlturm.
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
FI931599A0 (fi) Bensimidazoler, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning
DE60008400D1 (de) Triazolopyrimidinderivate
EP1001212A3 (de) Lagesperrvorrichtung für automatisch verstellbare Leuchte
PT1204659E (pt) Benzofuranos serotoninergicos
MX9204179A (es) Derivados de imidazo(2,1-b)benzotiazola-3-acetamida, su preparacion y su aplicacion en terapeutica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242457

Country of ref document: EP